M.D. Anderson Cancer Center
To learn if routine symptom monitoring using questionnaires during chemotherapy and/or radiation therapy in patients with PDAC improves patient health-related quality of life and experience with care.
2.1 Primary Objectives • To determine whether implementing routine ePRO symptom monitoring during NAT in patients with PDAC improves patient health-related quality of life (HRQoL) and experience with care compared with the pre-implementation period. o To capture participant HRQoL and experience, the primary outcomes will be measured using the PROMIS-16 and CAHPS Cancer Care Survey , respectively.
Eligibility Criteria * Age ≥18 years * Participants must have histologically confirmed PDAC that is respectable, borderline respectable, or locally advanced with potential for curative intent resection as defined by MD Anderson Cancer Center (Appendix V) * Participants must be eligible to receive systemic neoadjuvant therapy (chemotherapy +/- radiation therapy) with intent for curative resection * Participants who will receive neoadjuvant therapy at an MD Anderson facility including Texas Medical Center and Houston area locations * Participants must be able to understand English or Spanish *…
Standard of Care
Arctuva estimate
Verify or correct the compensation shown for this listing.